Tissue-agnostic Approval of HER2-targeted Therapy
Fam-trastuzumab deruxtecan-nxki was approved for HER2-positive tumors, regardless of the tissue of origin. The U.S. Food and Drug Administration...
Progress Against Cancer
Fam-trastuzumab deruxtecan-nxki was approved for HER2-positive tumors, regardless of the tissue of origin. The U.S. Food and Drug Administration...
Mirvetuximab soravtansine-gynx was approved for certain ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA)...
The BCR-ABL inhibitor ponatinib was approved for some patients with acute lymphoblastic leukemia. The U.S. Food and Drug Administration...
Lisocabtagene maraleucel was approved for some patients with advanced CLL or SLL. The U.S. Food and Drug Administration (FDA)...
Tislelizumab-jsgr received its first FDA approval to treat certain esophageal cancers. The U.S. Food and Drug Administration (FDA) has...
A new treatment regimen that includes a Bruton’s tyrosine kinase inhibitor was approved for follicular lymphoma. The U.S. Food...
First-line nivolumab with chemotherapy was approved for bladder cancer. The U.S. Food and Drug Administration (FDA) has approved nivolumab...
The FDA has approved inotuzumab ozogamicin for pediatric patients with certain leukemias. The U.S. Food and Drug Administration (FDA)...
The FDA has approved amivantamab-vmjw, both alone and in combination with chemotherapy, for the treatment of certain non-small cell...
The FDA has approved osimertinib plus chemotherapy for non-small cell lung cancer with EGFR mutations. The U.S. Food and...